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Abstract
Background: Previous studies conducted on the association between diabetes and the risk of endometrial cancer
have reported controversial results that have raised a variety of questions about the association between diabetes
and the incidence of this cancer. Thus, the aim of this systematic review and meta-analysis was to more precisely
estimate the effect of diabetes on the risk of endometrial cancer incidence.
Methods: All original articles were searched in international databases, including Medline (PubMed), Web of
sciences, Scopus, EMBASE, and CINHAL. Search was done from January 1990 to January 2018 without language
limitations. Also, logarithm and standard error logarithm relative risk (RR) were used for meta-analysis.
Results: A total of 22 cohort and case-control studies were included in this meta-analysis, of which 14 showed
statistically significant associations between diabetes and risk of endometrial cancer. Diabetes was associated with
increased risk of endometrial cancer (RR = 1.72, 95% CI 1.48–2.01). The summary of RR for all 9 cohort studies was
1.56 (95% CI 1.21–2.01), and it was 1.85 (95% CI 1.53–2.23) for 13 case control studies. The summary of RR in
hospital-based studies was higher than other studies. Thirteen of the primary studies-controlled BMI as a
confounding variable, and the combined risk of their results was 1.62 (95% CI 1.34–1.97).
Conclusions: Diabetes seems to increases the risk of endometrial cancer in women, and this finding can be useful
in developing endometrial cancer prevention plans for women having diabetes.
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Background
A recent study conducted by Lortet-Tieulent, J and col-
league show that endometrial cancer is the sixth most
commonly occurring cancer in women and the 15th
most commonly occurring cancer overall. There were
over 380,000 new cases in 2018 [1]. Also, about 142,000
women are diagnosed with endometrial cancer annually
worldwide, and about 42,000 women lose their life due
to endometrial cancer. The usual curve of endometrial
cancer indicates that most cases are diagnosed after
menopause, and the highest incidence rate is around the
seventh decade of life [2]. The disease is more than 10
times common in North America and Europe than in
less developed countries [3]. The incidence and the mor-
tality rate of endometrial cancer increased during 2006
and 2010 [4]. Estrogens, both internal and external, play
an important role in increasing endometrial cancer [5].
Several studies have shown that the risk of endometrial
cancer increases with older age, early menstruation, late
menopause, obesity, family history of endometrial cancer
(especially among close relatives), exposure to radiation,
infertility (especially due to polycystic ovarian syn-
drome), and long-term use of estrogens for hormone
therapy [4–7]. Estrogens, both internal and external, play
an important role in increasing endometrial cancer.
Multiple studies have claimed a positive association be-
tween diabetes and incidence of endometrial cancer with
several biological mechanisms [8]. However, a previous
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systematic review and meta-analysis was performing by
Friberg and colleges [8] but growing several publications
afterwards and also considering new variables in ad-
justed models, we felt to design an updated system-
atic review and meta-analysis in order to show any
posible relationship between diabetes and endometrial
cancer.
Methods
This systematic review was performed according to the
Meta-Analyses of Observational Studies in Epidemiology
(MOOSE) and Strengthening the Reporting of Observa-
tionally Studies in Epidemiology (STROBE) guidelines
for reviews of analytical observational studies (case-con-
trol and cohort) [2, 9, 10].
Search strategy
All original published articles were searched in inter-
national databases, including Medline (PubMed), Web
of sciences, Scopus, EMBASE, and CINHAL. Search was
done from January 1990 to January 2018 without lan-
guage limitations. The keywords were Diabetes, Diabetes
Mellitus (type 1 and 2), Insulin Dependent, IDDM,
NIDDM, Noninsulin Dependent, Endometrial Stromal
Tumors, Endometrial Neoplasms, and Endometrial. The
selected studies were limited to observational studies on
humans.
The primary search results were reviewed, and some
of the articles were eliminated after reviewing their title
and an abstract. Inclusion and exclusion criteria were set
by 2 researchers separately (YM, FV) (Fig. 1).
Fig. 1 Flow Diagram of the Literature Searches and Study Selection
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Eligibility criteria
A published study had to meet the following inclusion
criteria:
(1) original article, (2) case-control or cohort study, (3)
human population, (4) diabetes and patients with dia-
betes as the main independent variable, and (5) endo-
metrial cancer as the dependent variable. Case reports,
reviews, animal studies, and case control or cohort stud-
ies with crude estimates about the effect of diabetes on
the risk of endometrial cancer were removed from the
tabulation. The authors resolved all disputes during the
collection, compilation, and analysis of data.
Data extraction
Two researchers evaluated all included articles inde-
pendently. They assessed the disagreement, if any, and
in case an agreement was not reached, a third author
(LS) evaluated the study. Two independent matched re-
viewers extracted the data according to a uniform Excel
sheet. Then, a structured checklist was used to extract the
following information: (1) author, (2) year of publication,
(3) type of study, (4) country, (5) study population, (6) age
of women, (7) sample size, (8) type of diabetes, (9) meas-
urement, and (10) adjusted variables of association.
Statistical analysis
In the meta-analysis, 3 measures of association were
used: (1) odds ratio (case-control and population-based
case-control studies), (2) relative risk (cohort and popu-
lation cohort studies), and (3) hazard ratio (cohort and
population-based cohort studies). As the frequency of
endometrial cancer was relatively low, the odds ratio in
the case-control and population based case-control
studies and the risk ratio in the cohort and population-
based cohort studies yielded similar estimates of rela-
tive risk (RR) [11].
Logarithm and standard error logarithm relative risk
(RR) were used for the meta-analysis. DerSimonian and
Laird method was used to compute the pooled estimate
of relative risk (RR) with confidence interval (CI 95%)
using random models [12]. Because the test for hetero-
geneity was statistically significant in some analyses, the
random effects models were used to estimate RR. In this
study, w Cochran’s Q test and I2 statistic were used to
evaluate statistical heterogeneity between studies [13]. In
addition, a meta-regression and subgroup analysis was
performed to assess the source of heterogeneity between
studies. Moreover, publication bias was assessed by fun-
nel plot and Egger and Begg’s test [14, 15]. Statistical
analysis was performed using STATA 14.0 (Stata Corp,
College Station, TX, USA), and statistical significance
was set at p < 0.05.
Results
Study characteristics
A total of 22 studies were included in this meta-analysis
(Fig. 1), of which 9 were cohort and population cohort
studies [4–6, 16–21] (Table 1) and 13 were case-control
and population case-control studies [22–34] (Table 2).
Also, 12 studies were conducted in the USA [4, 5, 16,
19, 20, 22, 27, 29–32, 34], 4 in Sweden [17, 18, 21, 33], 2
in Italy [25, 26], 1 in Canada [23], 1 in Norway [6], 1 in
Mexico [28], and 1 in Japan [24]. The case-control and
population case-control studies (n = 13) comprised 22,
392 controls and 7698 endometrial cancer cases.
The overall and individual results of 22 cohort and case-
control studies are shown in Fig. 2. Of the 22 studies, 14
showed statistically significant associations between
diabetes and risk of endometrial cancer. Occurrence
of diabetes had an association with increased risk of
endometrial cancer (RR = 1.72, 95% CI 1.48–2.01)
(Figs. 2 and 3). The results demonstrated heterogen-
eity of the studies (I2 = 66.7%; P < 0.0001). However,
no evidence of publication bias was found based on
the results of the Egger’s test (Egger’s test: t = 1.90,
P = 0.072, 95% CI: − 0.04-0.91).
Subgroup analysis
The subgroup analysis was conducted based on the
study design, and variables adjustment (Table 3). Individ-
ual study results and the overall summary results for 8
cohorts and 7 population-based, 2 hospital-based, and 5
case-control studies investigating the effect of diabetes
on the risk of endometrial cancer in women are shown
in Table 3. The results indicated that the summary of RR
for all the 8 cohort studies combined was 1.52 (95% CI
1.16–2.00), and heterogeneity among these studies was
significant (Q = 3.03, I2 = 70.7%; P = 0.001). The sum-
mary of RR for all the 7 population-based case–control
studies was 1.55 (95% CI 1.37–1.75), however, heterogeneity
among these studies was not significant (Q = 6.88, I2 =
0.0%; P = 0.461). In addition, the summary of RR for all the
5 case-control studies was 2.31 (95% CI 1.81–2.96), but het-
erogeneity was not significant (Q = 6.69, I2 = 22.7%; P =
0.270). Also, the summary of RR was higher in hospital-
based studies than in other studies [RR = 4.10 (CI 95%
2.09–8.01), heterogeneity was Q = 4.12, I2 = 0.0%, P =
0.402]. According to the results in Table 3, the summary of
RR in hospital-based studies was higher than in other stud-
ies. Also, 13 of the primary studies-controlled BMI as a
confounding variable, and the combined risk of their results
was 1.62 (95% CI 1.34–1.97, test for heterogeneity: Q =
4.14, I2 = 71.0%, P = 0.0001). However, 4 of the primary
studies-controlled weight as a confounding variable, and
the combined risk of their results was 2.45 (95% CI 1.14–
5.26, test for heterogeneity: Q = 2.53, I2 = 21.0%, P = 0.021).
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Table 1 The Main Characteristics of Cohort and Population-based Cohort Studies on Diabetes and Endometrial Cancer Risk
Authors Year Type of
study
Country Study population Age Sample
size
Type of
diabetes
Measurement of association Controlled variables
Al Hilli. M, et al. [16] 2015 Cohort USA database for the
records of all
patients who
underwent primary
surgical intervention
for EC, from January
1, 1999, through
December 31, 2008.
All age 1303 Diabetes HR: 1.01; % 95 CI
(0.72,1.42)
Age, BMI
Friberg. E, et al. [17] 2007 Cohort Sweden Exposed group: 1628
women with self-
reported DM or DM
from national inpatient
register
Comparison group:
35145 women
without self-reported
DM or DM from
national inpatient
register
50–83 36,773 Diabetes RR: 1.94; % 95
CI(1.23,3.08)
Age, BMI, total
physical activity
Anderson. K, et al.[5] 2001 Cohort USA Exposed group: 1325
women with self-
reported DM
Comparison group:
23150 women
without self-
reported DM
55–69 24,475 Diabetes RR: 1.43; % 95
CI(0.98,2.09)
Age, BMI, BMI2,
WHR, ovulatory
span, gravidity,
PMH, menstrual
irregularities,
hypertension
Lindemann. K, et al. [6] 2008 Cohort Norway Norwegian women
during 15.7 years
of follow-up.
All age 36,761 Diabetes RR: 3.84 (% 95 CI:
1.92,5.11)
Age
Folsom. A, et al. [20] 2004 Cohort USA Exposed group: 42
women with
self-reported DM
and an endometrial
cancer diagnosis
Comparison group:
373 women with
self-reported DM
and an endometrial
cancer diagnosis
55–69 415 Diabetes RR: 2.38 (% 95 CI:
1.05,5.37)
Age, extent of
endometrial
cancer at diagnosis
Luo. J, et al. [4] 2014 Cohort USA Women’s Health
Initiative
50–79 88,107 Diabetes HR: 1.16 (% 95 CI:
0.90,1.48)
Age, BMI
Terry. P, et al. [21] 1999 Cohort Sweden Exposed group: 142
women with
self-reported DM
Comparison group:
10012 women
without self-
reported DM
42–81 10,154 Diabetes RR: 1.60 (% 95 CI:
0.20,11.30)
Age, physical
activity, weight,
parity
Coughlin. S, et al. [19] 2004 Cohort USA Exposed group: 33
women with
self-reported DM
Comparison group:
448 women
without self-
reported DM
> 30 481 Diabetes RR: 1.33 (% 95 CI:
0.92,1.90)
Age, race, education,
BMI, smoking, alcohol,
red meat, citrus fruit
and juice, vegetables,
physical activity, PMH,
parity, age at menarche,
age at first live birth,
menopausal status, OC
esLambe. M, et al. [18] 2011 Cohort Sweden individuals that took
part in routine
health checkups
and primary care
patients referred
for laboratory testing
All age 230,737 Diabetes HR: 1.46(% 95 CI
1.09,1.96
Age
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Table 2 The Main Characteristics of Case-Control and Population Case-Control Studies on Diabetes and Endometrial Cancer Risk
Authors Year Country Control subjects
(selection methods)
Age Sample size Type of
diabetes
Measurement
of association
Controlled variables
Weiderpass. E, et al. [33] 2000 Sweden Control women were
randomly selected from
a continuously updated
population register that
includes all residents.
50–74 Case(709) Diabetes OR: 1.7 (% 95 CI:
1.2,2.3)
Age, age at menarche,
parity, age at last birth,
age at menopause,
smoking, OC, PMH, BMI
Control(3368)
T(4077)
Shoff. SM, et al. [30] 1998 USA Community controls
were selected
randomly from lists
40–79 Case(723) Diabetes OR: 1.10 (% 95 CI:
0.66,1.86)
Age, BMI, smoking,
PMH, parity, education
Control(2291)
T(3014)
Lucenteforte. E, et al. [25] 2007 Italy Controls women
admitted to the
same network of
hospitals
18–79 Case(777) Diabetes OR: 2.0 (% 95 CI:
1.4,2.9)
Age, year of interview,
study center, education,
parity, menopausal status,
OC and HRT use
Control(1550)
T(2327)
Friedenreich. CM, et al. [23] 2011 Canada Controls selected
from the Alberta
Cancer Registry
30–79 Case(515) Diabetes OR: 1.31(95% CI:
1.03,1.67)
Age, parity, education,
age at menarche, hormone
therapy, age at menopause,
history of Type 2 diabetes,
hormone contraception, oral
and non-oral hormone use,
history of angina, history of
stroke, history of thrombosis,
smoking and alcohol
consumption
Control(962)
T(1447)
Saltzman. BS, et al. [29] 2007 USA Controls selected from
Women’s Contraceptive
and Reproductive
Experiences (CARE)
breast cancer study
45–74 Case(1303) Diabetes OR: 1.7(% 95
(CI: 1.2, 2.3)
Country, age, reference
year, body mass index,
and menopausal hormone
use
Control(1779)
T(3082)
Parazzini. F, et al. [26] 1999 Italy Controls selected
from same network
of hospitals where
cases had been
identified.
28–74 Case(752) Diabetes OR: 3.1
(% 95 CI: 2.3,4.2)
Age, calendar year,
education, BMI, parity,
OC, PMH, age at
menopause, hypertension,
smoking
Control(2606)
T(3358)
Wartko. PD, et al. [32] 2017 USA Control were randomly
selected from all other
women with delivery
records from 1987
to 2013.
All age Case(593) Diabetes OR: 1.80 (% 95 CI:
1.22,2.65)
Race/ethnicity, year of
delivery, maternal age
at delivery, and body
mass index
Control(5743)
T(6336)
Soliman. PT, et al. [31] 2006 USA Controls patient samples
were obtained through
a low-risk cancer
screening program
All age Case(117) Diabetes OR: 1.87 (%95, CI:
0.77,4.54)
Lower serum
adiponectin level,
age, BMI, and
hypertension
Control(238)
T(355)
Rubin. GL, et al.[27] 1990 USA population controls,
matched for place of
residence and age
20–54 Case(196) Diabetes OR: 1.80 (%95, CI:
0.90,3.60)
Age
Control(986)
T(1182)
Brinton. L A, et al. [22] 1992 USA Population controls
random digit dialing
for younger controls
and health care
financing administration
for older controls, older
controls were matched
on age, race and zip code
20–74 Case(405) Diabetes OR: 1.95 (%95, CI:
1.10,3.60)
Age, education,
number of births,
weight, OC, PMHControl(279)
T(684)
Inoue. M, et al. [24] 1994 Japan hospital control who
underwent hysterectomy
due to benign gynecological
tumors, matched on year
of admittance to hospital
and age
22–79 Case(143) Diabetes OR: 7.75 (%95, CI:
1.52,40.0)
Age, parity, cancer
history, hypertension,
obesityControl(143)
T(286)
Weiss. J M, et al. [34] 2006 USA Population that matched
on age
45–75 Case(1281) Diabetes OR: 1.58 (%95, CI:
1.20,2.07)
Age, PMH, BMI,
county, referent
year, tumors
aggressiveness
Control(1779)
T(3060)
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Also, the summary of RR of primary studies, whose re-
sults were adjusted based on BMI showed a less value
compared to summary of RR of primary studies, whose
results were adjusted based on weight control (1.62; 95%
CI 1.34–1.97 Vs 2.45; 95% CI 1.14–5.26). Physical activ-
ity was adjusted in 4 primary studies, and the summary
of RR based on controlling this variable was 1.89 (95%
CI 1.22–2.94, test for heterogeneity Q = 6.08, I2 = 50.6%,
P = 0.108) (Table 3).
Discussion
The results of this meta-analysis showed that women
with diabetes had a 72% increased risk of endometrial
cancer compared to those without diabetes as sup-
ports the previous meta-analysis conducted by E.
Friberg et al. (31) in 2007. Also, other studies have
shown that diabetes increased the risk of endometrial
cancer, which is in line with the results of the present
study [5, 6, 16, 23, 26, 32, 35].
Fig. 2 Association between Diabetes and Risk of Endometrial Cancer
Table 2 The Main Characteristics of Case-Control and Population Case-Control Studies on Diabetes and Endometrial Cancer Risk
(Continued)
Authors Year Country Control subjects
(selection methods)
Age Sample size Type of
diabetes
Measurement
of association
Controlled variables
Salazar. M E, et al.[28] 2000 Mexico Hospital, from
primary health
center i.e. outpatient,
matched on age
NA Case(85) Diabetes OR: 3.60 (%95, CI:
1.70,7.40)
Age, an ovulatory
index, smoking,
physical activity,
menopausal status,
hypertension, BMI
Control(668)
T(753)
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Based on subgroup analysis, the risk of endometrial
cancer in case-control studies was higher than in cohort
studies, and a higher risk was observed in hospital-based
studies compared to population-based studies. [36–38].
Since the results of case-control and hospital-based
studies are more prone to be affected by con-
founders therefore the calculated risk might be over-
estimated. [39–41].
In our meta-analysis, heterogeneity was 66.7% for
overall risk, which was reduced by subgroup analysis
based on type of study, so the heterogeneity for each
group for RR in cohort studies, case-control studies,
population-based studies, and hospital-based studies
were 70.7, 22.7, 0, and 0%, respectively. Furthermore, in
this study, it was found that the levels of heterogeneity
in physical activity, weight, and BMI had decreased
remarkably. It can be concluded from the analysis that
the causes of heterogeneity in determining the overall
risk of endometrial cancer in women with diabetes in
the present meta-analysis were type of study, adjusted
co-variables and geographical area (Fig. 2).
Obesity, which is one of the most important factors in
diabetes, can cause hormonal imbalances in the body,
and this in turn predisposes a person to endometrial
cancer [26, 42–44]. One of the risk factors for type 2
diabetes is obesity, which is also a major risk factor for
endometrial cancer. Although the precise mechanisms
and pathways are uncertain, it could be hypothesized
that endometrial carcinogenesis is that exposure of the
endometrium to excess estrogen unopposed by proges-
terone increases the mitogen activity of endometrial cells
[45, 46]. In this meta-analysis the summary of RR of
Fig. 3 Association between Diabetes and Risk of Endometrial Cancer by Type of Study
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primary studies, whose results were adjusted based on
BMI showed a less value compared to summary of RR of
primary studies, whose results were adjusted based on
weight control. In women with obesity the levels of es-
tradiol and estrogen are higher than women with normal
weight, [47, 48], and this could be one the possible rea-
son for the increase risk of endometrial cancer because
of obesity [48]. However, results of several studies
showed that other factors, such as higher insulin levels
and growth factors, may also increase the risk of endo-
metrial cancer in women with obesity [49, 50]. More-
over, long-term insulin therapy may also be responsible
for increased risk of endometrial cancer in women with
diabetes (31).
In this study, the authors performed subgroup analysis
based on type of primary studies, geographical area, and
adjusted covariate. However, we could not perform sub-
group analysis based on type of diabetes (type 1 and type
2) because the early studies did not specify or separate
the types of diabetes. Diabetes is a chronic disease,
whose diagnosis may not be accurate and specific, in
which case it would lead to classification bias (non-dif-
ferential misclassification). Therefore, the overall results
obtained from primary studies should be interpreted
with caution.
However most of included case-control and cohort
studies in this meta-analysis controlled the variables of
obesity and sedentariness but it is of utmost importance
to consider the effect of confounding variables (seden-
tariness, hormonal disorders, and obesity) on determin-
ing the relationship between diabetes and risk of
endometrial cancer in women. The major strength of
this updated meta-analysis in compare to previous one
is that more primary studies identified and included [8],
therefore distinguished effects of diabetes on risk of
developing endometrial cancer based on adjustments to
BMI/weight presented with larger sample size (larger
effect size).
Limitations
Included primary studies did not mention the duration
of diabetes and type of treatment (oral anti hypergly-
cemic agents and/or insulin). Furthermore, identifying
women with diabetes in the primary studies was almost
based on their self-reports. Since the primary studies did
not consider type of diabetes therefore it was not pos-
sible to estimate the possible risk separately in in type 1
and type 2 diabetes.
Conclusions
Diabetes seems to increases the risk of endometrial can-
cer in women, and this finding can be useful in develop-
ing endometrial cancer prevention plans for women
having diabetes.
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